ISI, a leading provider of software and services for the life sciences industry, today announced that it has acquired Apyx, Inc. The merger adds muscle to ISI’s already-growing professional services business, which saw a 26 percent increase in sales from 2007 to 2008, and enhances the company’s broad range of offerings in submissions management and outsourcing. The two companies’ shared commitment to customer service and responsiveness make the merger a natural fit.
“This addition to ISI enhances our flexible and holistic suite of services and software to the regulatory space that is unmatched in the marketplace,” said Jinsoo Kim, President and CEO of ISI. “Industry leadership and experience from Apyx helps fuel our mission of helping bring life-changing therapies to market safely and efficiently. The two companies have shared a vision for years – now we are driving together to reach a common goal.”
ISI currently provides 13 out of the top 20 pharmaceutical companies with ongoing, repeat services. Over the last decade, the company has helped biopharmaceutical companies all over the world bring dozens of therapies through regulatory approval to patients in need. The acquisition helps ISI strengthen its capabilities to offer clients a mix of process, technology, data and operational services that respond to today’s complex submission environment.
“We are joining forces with ISI because there is a huge opportunity to leverage each other’s strengths,” said Ken VanLuvanee, CEO, President and Founder of Apyx, Inc. “With ISI’s deep resources and expertise in Europe and Asia, we will be able to address the diverse range of submission requirements across the globe.” Ken VanLuvanee joins ISI as Vice President of Global Professional Services, reporting to Paul Chung, Executive Vice President. VanLuvanee will be leading the effort to further expand ISI’s Professional Services capabilities, utilizing his prior experiences within the consulting business around document management, business process improvement, CDISC submission services and program management. Ken will continue to be an active contributor at various industry forums such as HL7, DIA, and across various standards’ development initiatives.
ISI makes the acquisition at a time of flux for the pharmaceutical industry. In the wake of transformational new regulations and a host of economic and competitive factors, life sciences firms are dealing with a complex global marketplace they have never seen before.
Diverse and ever-changing regulatory standards across regions, the need to expand into emerging markets, and increasing pressure to collaborate with partners and oversee local operations are all contributing to the new era of unparalleled complexity. With the acquisition of Apyx, ISI will deliver more efficient and standardized processes and systems, enable operational alignment around the globe, and facilitate a more effective exchange of information to help clients navigate these new challenges.
About Image Solutions, Inc. (ISI)
Founded in 1992, Image Solutions, Inc. (imagesolutions.com) is a proven market leader in providing submissions solutions, process services and consulting to Life Sciences companies as a way to improve clinical and regulatory processes that bring new medicines to market. ISI was among the first professional services firms to deliver electronic submissions to the industry and since has delivered thousands of electronic and eCTD submissions. ISI serves the top 50 pharmaceutical and biotech organisations as well as the top companies in other regulated industries.
ISI is a privately held company with headquarters in Whippany, New Jersey and operations throughout the U.S., Europe and Asia. ISI also remains committed to giving back to society and sharing its success with others by donating 10 percent of annual net profits to over 20 recognised charitable organisations.
Image Solutions, Inc., ISIToolBox, eCTDXPress, ISIPublisher and ISIRegTracker are trademarks or registered trademarks of Image Solutions, Inc. which may be registered in the United States and internationally. Other brand names may be trademarks or registered trademarks of others.